Research Focus

Former Employee. Human Resources; Clinical Nurse IV

Recent additions – View all

1. Prospective evaluation of the utility of the serum free light chain assay (FLC), clonal Ig V(L) gene identification and troponin I levels in a phase II trial of risk-adapted intravenous melphalan with adjuvant thalidomide and dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis

   Conference Paper

   Comenzo, R. L.; Zhou, P.; Reich, L.; Costello, S.; Quinn, A.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; more...
   CRC Press (2004)

   Fulltext@MSK | Save
2. Risk-adapted intravenous melphalan with adjuvant thalidomide and dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis: Interim report of a phase II trial

   Conference Paper

   Comenzo, R. L.; Zhou, P.; Reich, L.; Costello, S.; Quinn, A.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; more...
   CRC Press (2004)

   Fulltext@MSK | Save
3. Risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL): Interim results of a phase II study

   Meeting Abstract

   Cohen, A. D.; Zhou, P.; Reich, L.; Quinn, A.; Fircanis, S.; Drake, L.; Hedvat, C.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; more...
   Blood (2004)

   Fulltext@MSK | Save